Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Northern Sydney Local Health District has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner within 1 distinct art unit. This indicates a focused prosecution effort for the health district's current biotechnological innovations. The fact that the action is in 1 distinct art unit suggests a consistent application of pharmaceutical examination standards.
WANG, CHANG YU is the busiest examiner for this portfolio, currently managing 1 pending office action. As the only examiner involved, Wang's specific interpretation of biotechnology patent law will be a factor in the outcome of this filing. The 1 pending office action represents the entirety of the district's current active prosecution in this field. This focused prosecution environment allows for a clear and direct path toward resolving the pending matter in the Biotechnology & Pharmaceuticals sector.
For practitioners, the 1 pending office action requires a targeted response that addresses the specific technical issues raised by the examiner. With 1 distinct examiner and 1 distinct art unit, the health district can maintain a singular focus on resolving the issues raised in this pending matter. Strategy should be informed by the specific trends and requirements of the Biotechnology & Pharmaceuticals sector. Efficiently navigating the requirements of the 1 distinct art unit will be essential for the health district's biotechnological intellectual property strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18069546 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISORDERS | WANG, CHANG YU | 1d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18069546 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISORDERS | WANG, CHANG YU | 1d overdue |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18069546 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF NEURODEGENERATIVE DISORDERS | WANG, CHANG YU | 1675 | §103§112 | Non-Final OA | 1d overdue | Pending | Dec 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNorthern Sydney Local Health District has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Chang Yu Wang has the most, with 1 of Northern Sydney Local Health District's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
